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Abstract
Background: Aberrant Wnt signaling activation occurs commonly in colorectal carcinogenesis, leading to
upregulation of many target genes. APC (adenomatous polyposis coli) is an important component of the β-catenin
destruction complex, which regulates Wnt signaling, and is often mutated in colorectal cancer (CRC). In addition to
mutational events, epigenetic changes arise frequently in CRC, specifically, promoter hypermethylation which silences
tumor suppressor genes. APC and the Wnt signaling target gene ITF2 (immunoglobulin transcription factor 2) incur
hypermethylation in various cancers, however, methylation-dependent regulation of these genes in CRC has not been
studied in large, well-characterized patient cohorts. The microsatellite instability (MSI) subtype of CRC, featuring DNA
mismatch repair deficiency and often promoter hypermethylation of MutL homolog 1 (MLH1), has a favorable outcome
and is characterized by different chemotherapeutic responses than microsatellite stable (MSS) tumors. Other epigenetic
events distinguishing these subtypes have not yet been fully elucidated.
Methods: Here, we quantify promoter methylation of ITF2 and APC by MethyLight in two case-case studies nested in
population-based CRC cohorts from the Ontario Familial Colorectal Cancer Registry (n = 330) and the Newfoundland
Familial Colorectal Cancer Registry (n = 102) comparing MSI status groups.
Results: ITF2 and APC methylation are significantly associated with tumor versus normal state (both P < 1.0×10-6). ITF2 is
methylated in 45.8 % of MSI cases and 26.9 % of MSS cases and is significantly associated with MSI in Ontario (P = 0.002)
and Newfoundland (P = 0.005) as well as the MSI-associated feature of MLH1 promoter hypermethylation (P = 6.72×10-4).
APC methylation, although tumor-specific, does not show a significant association with tumor subtype, age, gender, or
stage, indicating it is a general tumor-specific CRC biomarker.
Conclusions: This study demonstrates, for the first time, MSI-associated ITF2 methylation, and further reveals the
subtype-specific epigenetic events modulating Wnt signaling in CRC.
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Background
Colorectal cancer (CRC) is one of the most common
cancers in the Western world and is marked by a high
mortality rate [1]. Early detection of CRC is the key to
improved survival rates [2]. Another factor affecting
disease prognosis is CRC subtype [3]. The microsatellite
instability (MSI) subtype of CRC accounts for approxi-
mately 15 % of colorectal cancers [4]. MSI tumors are
distinguished by defects in the DNA mismatch repair
system which leads to mutational insertions and dele-
tions in short tandem repeats (microsatellites) of DNA
[5]. MSI is most often due to promoter hypermethyla-
tion and silencing of the MutL homolog 1 (MLH1) mis-
match repair gene. Microsatellite stable (MSS) tumors
account for 85 % of CRCs and exhibit chromosomal
instability, including numerous chromosomal duplica-
tions, deletions and rearrangements [6]. MSI tumors
differ from MSS tumors in several ways; MSI CRCs
exhibit proximal colonic location, increased lymphocytic
infiltration, and poorer response to chemotherapeutic
drugs [7, 8]. MSI CRCs also demonstrate better progno-
sis at stages I-III, however, some studies suggest poor
prognosis at stage IV, though metastatic MSI cases are
rare [7, 9]. A third CRC subtype, the CpG island methyl-
ator phenotype (CIMP), is characterized by widespread
DNA hypermethylation of CpG-rich promoter islands.
CIMP can exist concurrently with either the MSI or
MSS phenotype, though it is more frequently found in
tandem with MSI and MLH1 hypermethylation [10].
The prognostic significance of CIMP is currently un-
defined and may be modified by MSI status, presence of
BRAF mutation, tumor stage, or other factors [11–13].
Recently, a classification system for further subtyping of
CRC has been proposed, consisting of four subtypes
[14]. One subtype consists mostly of MSI cases, while
the other three are able to categorize the remainder of
cases by Wnt signaling activation, metabolic dysregula-
tion, or mesenchymal activation.
The vast majority (up to 94 %) of CRCs feature dysreg-
ulation in the Wnt signaling pathway [15]. Wnt signaling
is important in normal development, cell growth and
proliferation, but when inappropriately activated may
also lead to tumor initiation and development [16]. In
canonical Wnt signaling, β-catenin accumulates within
the cell, enters the nucleus and activates transcription of
target genes, such as c-Myc and ITF2 (immunoglobulin
transcription factor 2) [17, 18]. ITF2 is also known as
transcription factor 4 (TCF4). In the absence of Wnt
signaling, a β-catenin destruction complex including
adenomatous polyposis coli (APC) targets β-catenin for
ubiquitination followed by proteasomal degradation
[17, 18]. In many cases of CRC, the APC gene is mu-
tated, rendering it incapable of binding to β-catenin,
which leads to β-catenin accumulation followed by its
nuclear translocation and subsequent activation of
downstream target genes [18].
Evidence for DNA methylation of the APC promoter
has been found in CRC. However, to what extent APC
methylation plays a role in colorectal carcinogenesis is
unclear, as a broad range of methylation levels has been
found in the literature, from 11 up to 63 % of tumors
methylated [19–23]. Conflicting reports exist regarding
the extent of APC methylation in MSI CRCs. Some
small-scale studies (MSI n ≤ 29) have suggested that
APC methylation may be associated with the MSI sub-
type, but others show no significant difference [21–27].
Still another study has found APC methylation to be
inversely correlated with CIMP but not MSI [28].
The role of ITF2, a Wnt signaling target gene, is less
understood in CRC. It is a target of Wnt signaling and is
overexpressed in colon cancers with Wnt dysregulation [29].
Its expression was reported elevated in some cancers with
aberrant Wnt signaling activation but decreased in others
[30, 31]. Among gastrointestinal malignancies, ITF2 methy-
lation has been reported in gastric cancer, but its methyla-
tion status has not been investigated in CRC [32, 33].
Our group has previously demonstrated associations
between the methylation status of key Wnt signaling
pathway regulatory genes and CRC subtype including
the extracellular Wnt antagonists DKK1 and SFRP1 as
well as Wnt5a which is involved in non-canonical Wnt
activity [34, 35].
In this study, we have examined the role of APC and
ITF2 methylation in two nested case-case studies in
CRC cohorts. These patients were recruited from two
distinct Canadian populations and the case groups were
stratified by their MSI status.
Methods
Study participants
Participants of this study were population-based primary
CRC cases recruited through the Ontario Familial Colo-
rectal Cancer Registry (OFCCR) and Newfoundland
Familial Colorectal Cancer Registry (NFCCR). Proce-
dures for patient accrual, biospecimen collection and
data collection for the OFCCR and NFCCR have been
previously described [36, 37]. Briefly, Ontario residents
between the ages of 20 and 74 diagnosed with
pathology-confirmed primary CRC between 1997 and
2000 were eligible for recruitment. Familial adenoma-
tous polyposis cases were excluded and in the current
study non-white patients were also excluded due to
the high prevalence of self-reported Caucasians in the
study (92.5 %). A total of 1168 participants have been
analyzed for MSI status (see Molecular analysis below)
of which 184 are MSI high (MSI-H). 165 of these MSI-
H cases had available DNA of high quality. A matched
case-case selection strategy was utilized to select 165
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patients with MSS tumors to match 165 patients with
MSI-H tumors by sex, stage at diagnosis and age quar-
tile. The 165 MSS tumors were selected from a total
of 384 MSS tumors available at the time this study
was undertaken. Population-based recruitment by the
NFCCR was similar to the OFCCR, with a recruitment
period from 1999 to 2003 of cases from provincial
tumor registries [37]. For the NFCCR, proxy consent
from living family members was obtained for deceased
patients leading to a high frequency of late-stage
patients. These tumor samples were not utilized in
order to maintain similar patient age and tumor stage
between the Ontario and Newfoundland populations.
102 tumor samples from 696 total CRC cases were
chosen from probands of the NFCCR, 51 of which
were MSI-H, matched to 51 MSS cases by sex, stage at
diagnosis and age quartile. Overall survival status,
along with other patient clinicopathological features,
is described in Table 1. Recurrence data was not avail-
able for all cases used in this study, thus was not
included in analysis. DNA from normal colonic mu-
cosa was also available for all patients. Of the 330
OFCCR and 102 NFCCR patients’ tumor samples
utilized, 47 were selected randomly for methylation
analysis of normal adjacent tissue. Patient data was
obtained through protocols approved by the Research
Ethics Boards of Mount Sinai Hospital, the University
of Toronto and Memorial University of Newfoundland.
All patients or their proxies provided informed consent.
Molecular analysis
DNA used to assess MSI status was extracted from
archival paraffin-embedded tumors microdissected to
enrich for tumor cells. MSI status was assessed using
National Cancer Institute guidelines using four or
more of the following markers: ACTC, BAT-25,
BAT-26, BAT-40, BAT-34C4, D10S197, D18S55,
D17S250, D5S346 and MYC-L. The numbers of posi-
tive markers used to define MSI status are: MSI high
(MSI-H), ≥30 % unstable markers; MSI low (MSI-L),
1–29 % unstable markers; MSS, 0 % unstable
markers [38]. Tumors with MSI-L status were not
included in this study.
Somatic T > A mutation of nucleotide 1799 in the BRAF
gene leading to the V600E mutation was determined by
allele-specific PCR as described previously [34].
Immunohistochemistry was used to determine pres-
ence of the mismatch repair proteins MLH1, MSH2,
MSH6 and PMS2. Protein staining was classified as
either present, absent, or inconclusive. Tumors with-
out positive staining for any of these proteins were
defined as mismatch repair deficient, as described
previously [39].
MethyLight analysis
The sensitive, semi-quantitative high-throughput Methy-
Light assay was used to analyze the methylation of APC
and ITF2 in tumor and normal colonic DNA of CRC
patients. DNA was treated with sodium bisulfite prior to
MethyLight according to protocol using the EZ DNA
Methylation Gold Kit (Zymo Research Corp, Orange,
CA). Primers and probe were used to amplify a region
within the CpG island of promoter 1A of APC. Forward
primer: 5′-GAACCAAAACGCTCCCCAT-3′. Probe: 5′-
CCCGTCGAAAACCCGCCGATTA-3′. Reverse primer:
5′-TTATATGTCGGTTACGTGCGTTTATAT-3′. Primers
and probe were designed within the promoter region of
ITF2. Forward primer: 5′-GAAGCGGTAATACGAATAA
GAGC-3′. Probe: 5′-ATTCCCGAAACCGAAATCGTTC
GCAAACC-3′. Reverse primer: 5′- AACTATTCTCGAAT
AAACGTCGC-3′. Alu-C4 was also amplified to normalize
the DNA input. Forward primer: 5′-GGTTAGGTATAGT
GGTTTATATTTGTAATT-3′. Probe: 5′-CCTACCTTAA
CCTCCC-3′. Reverse primer: 5′-ATTAACTAAACTAATC
TTAAACTCCTA-3′. Probes contained a 5′ fluorescent re-
porter dye and a 3′ quencher dye. Samples were analyzed
using the ABI 7500 RT-PCR thermocycler in 96-well plates
as previously described [40]. APC, ITF2 and Alu-C4 were
also amplified in exogenously methylated CpGenome DNA
(Millipore, Billerica, MA). The percent methylated refer-
ence (PMR) was calculated to assess the methylation using
the formula: (Gene of Interest/Alu-C4)sample/(Gene of Inter-
est/Alu-C4)CpGenomex100%. In order to ensure that DNA
quality was adequate, samples with an Alu-C4 threshold
cycle greater than 22 were deemed poor quality and re-
analyzed or removed from the study [41].
MLH1 methylation status was assessed by MethyLight
as described previously, with positive methylation
defined as PMR ≥ 10 % [42]. CIMP status was deter-
mined using the Weisenberger panel of markers, de-
scribed previously [43]. Briefly, MethyLight was used to
assess a 5-gene signature consisting of CACNA1G, IGF2,
NEUROG1, RUNX3 and SOCS1. Tumors were classified
as CIMP if 3 or more of 5 genes had PMR ≥ 10 % and
non-CIMP if 2 or fewer genes had PMR ≥ 10 %. CIMP
status was available for a subset of Ontario cases (285 of
330) and unavailable for Newfoundland cases.
Statistical analysis
Comparison of the methylation status of matched tumor
and normal DNA samples was performed using McNe-
mar’s test. Results were considered statistically significant if
two-sided P < 0.05. Pearson’s chi-square test was used to
measure associations between clinicopathological variables
and ITF2 and APC methylation in tumor DNA. Bonferroni
correction was used to account for multiple comparisons.
All analyses were performed using PASW Statistics 21
(SPSS Inc., Chicago, IL).
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Results
ITF2 promoter methylation in CRC tumors and normal
colonic mucosa
Patient clinicopathological features are shown in
Table 1 for MSI-H and MSS cases for the Ontario and
Newfoundland populations. We quantified promoter
methylation of ITF2 using MethyLight in CRC tumors
from Ontario and Newfoundland. To quantify ITF2
promoter methylation levels in both normal mucosa
and CRC tumor tissue we tested 47 randomly selected
normal-tumor pairs from Ontario and Newfoundland
CRC cases, of which 12 were MSI-H and 35 were
MSS. The mean PMR was 8.8 % in tumor DNA and
1.6 % in normal colonic DNA. Methylation levels
ranged from 0–31.1 % in tumor and 0–15.6 % in
normal colonic DNA. A PMR cut-off of 10 % was used
to dichotomize methylated and unmethylated samples.
McNemar’s test comparing methylation above this
cut-off in tumor and normal tissues in CRC patients
determined tumor methylation of ITF2 to be signifi-
cantly higher than normal colonic mucosa methylation
(P < 1.0×10-6). For ITF2 promoter methylation, com-
parable methylation levels were seen in CRC tumors
between the two populations, comprised of 165 MSI-H
and 165 MSS cases from Ontario and 51 MSI-H and 51
MSS cases from Newfoundland. In the Ontario cases the
mean PMR for all 330 cases was 8.5 %. Methylation values
ranged from 0–57.2 %. Using the PMR cut-off of 10 %,
34.2 % (113/330) of cases were considered positively
methylated in the Ontario cohort. In Newfoundland cases
the mean PMR for all 102 cases was 15.4 %. Methylation
Table 1 Clinicopathological features of primary colorectal
carcinomas of patients from Ontario and Newfoundland
No. of cases (%)
Ontario Newfoundland
MSS MSI-H MSS MSI-H
Cases of primary
colorectal carcinoma
165 165 51 51
Mean age (±SDa) 59.9 (9.3) 60.1 (9.8) 58.3 (10.2) 58.4 (10.2)
Age
<50 19 (11.5) 28 (17.0) 11 (21.6) 10 (19.6)
50+ 146 (88.5) 137 (83.0) 40 (78.4) 41 (80.4)
Sex
Male 74 (44.8) 74 (44.8) 26 (51.0) 26 (51.0)
Female 91 (55.2) 91 (55.2) 25 (49.0) 25 (49.0)
TNM Stage
1 38 (23.0) 38 (23.0) 12 (23.5) 11 (21.6)
2 84 (50.9) 85 (51.5) 26 (51.0) 27 (52.9)
3 34 (20.6) 39 (23.6) 10 (19.6) 12 (23.5)
4 9 (5.5) 3 (1.8) 3 (5.9) 1 (2.0)
Histological Grade
Low 16 (9.7) 10 (6.1) 4 (7.8) 7 (13.7)
Moderate 123 (74.5) 45 (27.3) 37 (72.6) 36 (70.6)
High 13 (7.9) 20 (12.1) 8 (15.7) 8 (15.7)
Unavailable 13 (7.9) 90 (54.5) 2 (3.9)
Locationb
Distal 108 (65.5) 15 (9.1) 37 (72.5) 9 (17.6)
Proximal 51 (30.9) 63 (38.2) 14 (27.5) 42 (82.4)
Unavailable 6 (3.6) 87 (52.7)
Histological Typec
Non-Mucinous 143 (86.7) 107 (64.8) 46 (90.2) 42 (82.4)
Mucinous 19 (11.5) 53 (32.1) 5 (9.8) 9 (17.6)
Unavailable 3 (1.8) 5 (3.0)
MMR Protein Status
Intact 148 (89.7) 26 (15.8) 50 (98.0) 4 (7.8)
Deficient 4 (2.4) 136 (82.4) 0 (0.0) 46 (90.2)
Unavailable 13 (7.9) 3 (1.8) 1 (2.0) 1 (2.0)
MMR Germline Mutation
No 164 (99.4) 124 (75.2) 51 (100.0) 39 (76.5)
Yes 1 (0.6) 41 (24.8) 0 (0.0) 12 (23.5)
MLH1 Methylation
Unmethylated 159 (96.4) 87 (52.7) 36 (70.6) 23 (45.1)
Methylated 5 (3.0) 78 (47.3) 1 (2.0) 28 (54.9)
Unavailable 1 (0.6) 14 (27.4)
BRAF V600E Mutation
No 146 (88.5) 95 (57.6) 46 (90.2) 25 (49.0)
Yes 15 (9.1) 66 (40.0) 2 (3.9) 20 (39.2)
Unavailable 4 (2.4) 4 (2.4) 3 (5.9) 6 (11.8)
Table 1 Clinicopathological features of primary colorectal
carcinomas of patients from Ontario and Newfoundland
(Continued)
CIMP Status
Negative 133 (80.6) 79 (47.9)
Positive 10 (6.1) 63 (38.2)
Unavailable 22 (13.3) 23 (13.9) 51 (100.0) 51 (100.0)
Survival Status
Alive 100 (60.6) 99 (60.0) 45 (88.2) 49 (96.1)
Deceased 65 (39.4) 66 (40.0) 6 (11.8) 2 (3.9)
ITF2 Methylation
Unmethylated 122 (73.9) 95 (57.6) 36 (70.6) 22 (43.1)
Methylated 43 (26.1) 70 (42.4) 15 (29.4) 29 (56.9)
APC Methylation
Unmethylated 112 (67.9) 103 (67.9) 33 (64.7) 28 (54.9)
Methylated 53 (32.1) 62 (37.6) 18 (35.3) 23 (45.1)
aStandard Deviation
bProximal tumor location includes lesions up to and including the
splenic flexure
cMucinous histology includes the presence of any mucin within the
tumor stroma
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values ranged from 0–95.4 %. Using the PMR cut-off of
10 %, 43.1 % (44/102) of cases were considered positively
methylated in the Newfoundland cohort.
APC promoter methylation in CRC tumors and normal
colonic mucosa
We quantified methylation of the APC promoter region in
tumor and matched normal colonic mucosa of 47 ran-
domly selected patients from both Ontario and New-
foundland. Mean methylation was 16.1 % in tumor DNA
and 2.6 % in normal colon. Methylation values ranged
from 0–60.2 % for tumor samples and from 0–11.9 % for
normal samples. A PMR cut-off of 10 % was used to
dichotomize methylated and unmethylated samples.
McNemar’s test comparing methylation above this cut-off
in tumor and normal tissues in CRC patients determined
tumor methylation of APC to be significantly higher than
normal colonic mucosa methylation (P < 1.0×10-6).
For APC promoter methylation, comparable methyla-
tion levels were seen in CRC tumors between the two
populations. The mean PMR in Ontario was 11.5 %.
Methylation values ranged from 0–92.2 %. For the
Newfoundland samples, the mean PMR was 13.9 %.
Methylation values ranged from 0–70.5 %. Using the
PMR cut-off of 10 %, 34.8 % of tumors (115/330) were
methylated in the Ontario cohort and 40.2 % of tumors
(41/102) were methylated in the Newfoundland cohort.
ITF2 methylation and clinicopathological features,
including MSI subtype, in two distinct CRC cohorts
We examined whether methylation of ITF2 in tumor
DNA was associated with patient clinicopathological fea-
tures. Methylation status was compared by Pearson’s
chi-square test between MSI-H and MSS cases. In On-
tario 26.1 % (43/165) of MSS cases compared to 42.4 %
(70/165) of MSI-H cases were methylated, with an odds
ratio (OR) of 2.09 [95 % confidence interval (CI) 1.31–
3.33], and P = 0.002. Similarly in Newfoundland 29.4 %
(15/51) of MSS cases and 56.9 % (29/51) of MSI-H cases
were methylated with OR of 3.16 (95 % CI 1.40–7.17),
and P = 0.005. Ontario and Newfoundland data was then
pooled for further analysis.
Due to our selection strategy and the association
between MSI and ITF2 methylation, further clinicopath-
ological associations were analyzed separately for MSI-H
and MSS cases, shown in Table 2. There was a signifi-
cant association between ITF2 promoter methylation
with MLH1 promoter methylation in MSI-H cases, P =
6.72×10-4, OR 1.88 (1.10–3.68). There was also a trend
towards an association between ITF2 methylation and
female gender in MSI-H cases, and ITF2 methylation
and CIMP in MSS cases, but this was not significant
using a conservative p-value adjusted for multiple com-
parisons. No other significant associations were found
for either MSS or MSI-H cases between ITF2 methylation
and early age of onset (<50 years), stage, grade, tumor loca-
tion, histological type, MMR protein status, MMR germline
mutation, BRAF V600E mutation, or survival status. Stage-
specific survival was also performed, to account for poten-
tial differences in early stage survival compared to stage IV
in MSI-H cases (data not shown). There was a trend to-
ward higher overall survival in stage I MSI-H cases with
ITF2 methylation, but results were not significant after
correction for multiple comparisons.
APC methylation and clinicopathological features,
including MSI subtype, in two distinct CRC cohorts
We examined whether methylation of APC in tumor
DNA was associated with patient clinicopathological fea-
tures in both cohorts. Methylation status was compared
by Pearson’s chi-square test between MSI-H and MSS
cases. In Ontario 32.1 % (53/165) of MSS cases were
methylated while 37.6 % (62/165) of MSI-H cases were
methylated with an OR (95 % CI) of 1.27 (0.81–2.00),
and P = 0.298. Similarly in Newfoundland 35.3 % (18/51)
of MSS cases were methylated and 45.1 % (23/51) of
MSI-H cases methylated with OR (95 % CI) of 1.51
(0.68–3.34), and P = 0.313.
We examined whether APC methylation was associated
with patient clinicopathological features in pooled CRC
cases from Ontario and Newfoundland. Results are shown
in Table 3. Methylation of APC was not found to be asso-
ciated with early age of onset (<50 years), sex, stage, grade,
tumor location, histological type, CIMP status, MMR pro-
tein status, MMR germline mutation, MLH1 methylation,
BRAF V600E mutation, or survival status.
Discussion
Understanding the genetic and epigenetic differences
amongst colorectal cancer subtypes is essential, as CRC
subtypes differ in their treatment options and offer dis-
tinct survival outcomes. The Wnt signaling pathway is
dysregulated in a majority of colorectal tumors and can
be altered at the extracellular, intracellular and gene tar-
get level [15, 34, 35]. We have shown that these changes
to the Wnt pathway also differ based upon microsatellite
instability status. We quantified the methylation status
of the ITF2 and APC promoter CpG islands in a nested
case-case study in two cohorts of colorectal carcinoma
from two different populations, comparing cases by MSI
status. We have demonstrated that the ITF2 promoter is
hypermethylated in tumor tissues compared with matched
normal mucosa, and further, MSI-H tumors are more likely
to incur promoter methylation compared with MSS tu-
mors. ITF2 promoter methylation was also significantly
associated with MLH1 promoter methylation, a common
occurrence in MSI-H tumors. Conversely, we found that
APC, an important intracellular regulator of Wnt signaling
Savio et al. BMC Cancer  (2016) 16:113 Page 5 of 11
Table 2 Associations between ITF2 methylation and clinicopathological features in tumor DNA. Analysis of 216 MSI-H and 216 MSS
CRC patients from Ontario and Newfoundland









OR (95 % CI)a P-value
Age
<50 24 (15.2) 6 (10.3) 1.552 (0.600–4.014) 0.361 24 (20.5) 14 (14.1) 1.567 (0.761–3.225) 0.220
50+ 134 (84.8) 52 (89.7) 93 (79.5) 85 (85.9)
Sex
Male 73 (46.2) 26 (44.8) 1.057 (0.577–1.935) 0.857 64 (54.7) 36 (36.4) 2.113 (1.222–3.655) 0.007
Female 85 (53.8) 32 (55.2) 53 (45.3) 63 (63.6)
TNM Stageb
1 36 (22.8) 14 (24.1) 0.720 (0.606–0.856) 0.193 31 (26.5) 18 (18.2) 5.167 (0.499–53.450) 0.321
2 78 (49.4) 32 (55.2) 57 (48.7) 55 (55.6)
3 32 (20.3) 12 (20.7) 28 (23.9) 23 (23.2)
4 12 (7.6) 0 (0.0) 1 (0.9) 3 (3.0)
Histological Gradeb
Low 16 (10.8) 4 (7.5) 2.000 (0.482–8.295) 0.624 9 (13.8) 8 (13.1) 0.728 (0.215–2.459) 0.514
Moderate 118 (79.7) 42 (79.2) 39 (60.0) 42 (68.9)
High 14 (9.5) 7 (13.2) 17 (26.2) 11 (18.0)
Locationc
Proximal 58 (37.9) 29 (50.9) 0.589 (0.319–1.089) 0.090 60 (89.6) 54 (87.1) 1.270 (0.432–3.735) 0.664
Distal 95 (62.1) 28 (49.1) 7 (10.4) 8 (12.9)
Histological Typed
Non-Mucinous 140 (90.3) 49 (84.5) 1.714 (0.705–4.167) 0.230 76 (66.7) 73 (75.3) 0.658 (0.360–1.202) 0.172
Mucinous 15 (9.7) 9 (15.5) 38 (33.3) 24 (24.7)
MMR Protein Status
Intact 143 (97.9) 55 (98.2) 0.867 (0.088–8.511) 0.902 21 (18.6) 9 (9.1) 2.283 (0.992–5.251) 0.048
Deficient 3 (2.1) 1 (1.8) 92 (81.4) 90 (90.9)
MMR Germline Mutation
No 157 (99.4) 58 (100.0) 0.730 (0.673–0.792) 0.544 89 (76.1) 74 (74.7) 1.074 (0.577–1.999) 0.822
Yes 1 (0.6) 0 (0.0) 28 (23.9) 25 (25.3)
MLH1 Methylation
Unmethylated 143 (96.0) 52 (100.0) 0.733 (0.674–0.798) 0.142 68 (58.1) 42 (42.4) 1.883 (1.095–3.238) 6.72x10-4
Methylated 6 (4.0) 0 (0.0) 49 (41.9) 57 (57.6)
BRAF V600E Mutation
No 141 (92.2) 51 (91.1) 1.152 (0.387–3.431) 0.799 70 (63.1) 50 (52.6) 1.537 (0.088–2.683) 0.130
Yes 12 (7.8) 5 (8.9) 41 (36.9) 45 (47.4)
CIMP Status
Negative 100 (96.2) 33 (84.6) 4.545 (1.208–17.100) 0.016 50 (61.7) 29 (47.5) 1.780 (0.908–3.489) 0.092
Positive 4 (3.8) 6 (15.4) 31 (38.3) 32 (52.5)
Survival Status
Alive 110 (69.6) 35 (60.3) 1.475 (0.790–2.755) 0.221 78 (66.7) 70 (70.7) 0.829 (0.464–1.478) 0.524
Deceased 48 (30.4) 23 (39.7) 39 (33.3) 29 (29.3)
aOdds ratio and 95 % confidence interval for methylated versus unmethylated
bOR and 95 % CI given for lowest stage/grade versus highest stage/grade
cProximal tumor location includes lesions up to and including the splenic flexure
dMucinous histology includes the presence of any mucin within the tumor stroma
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Table 3 Associations between APC methylation and clinicopathological features in tumor DNA. Analysis of 216 MSI-H and 216 MSS
CRC patients from Ontario and Newfoundland









OR (95 % CI)a P-value
Age
<50 20 (13.8) 10 (14.1) 0.976 (0.431–2.213) 0.954 23 (17.6) 15 (17.9) 0.994 (0.485–2.035) 0.986
50+ 125 (86.2) 61 (85.9) 108 (82.4) 70 (82.4)
Sex
Male 64 (44.1) 35 (49.3) 0.813 (0.460–1.436) 0.475 59 (45.0) 41 (48.2) 0.879 (0.509–1.520) 0.645
Female 81 (55.9) 36 (50.7) 72 (55.0) 44 (51.8)
TNM Stageb
1 27 (18.6) 23 (32.4) 0.391 (0.095–1.619) 0.147 32 (24.4) 17 (20.0) 0.653 (0.533–0.801) 0.306
2 79 (54.5) 31 (43.7) 64 (48.9) 48 (56.5)
3 30 (20.7) 14 (19.7) 31 (23.7) 20 (23.5)
4 9 (6.2) 3 (4.2) 4 (3.1) 0 (0.0)
Histological Gradeb
Low 12 (8.9) 8 (12.1) 0.600 (0.163–2.207) 0.724 8 (11.0) 9 (17.0) 0.770 (0.230–2.578) 0.467
Moderate 108 (80.0) 52 (78.8) 50 (68.5) 31 (58.5)
High 15 (11.1) 6 (9.1) 15 (20.5) 13 (24.5)
Locationc
Proximal 62 (44.0) 25 (36.2) 1.381 (0.763–2.499) 0.285 63 (85.1) 51 (92.7) 0.449 (0.135–1.495) 0.183
Distal 79 (56.0) 44 (63.8) 11 (14.9) 4 (7.3)
Histological Typed
Non-Mucinous 129 (89.6) 60 (87.0) 1.290 (0.534–3.114) 0.570 87 (68.5) 62 (73.8) 0.772 (0.418–1.426) 0.408
Mucinous 15 (10.4) 9 (13.0) 40 (31.5) 22 (26.2)
MMR Protein Status
Intact 132 (97.8) 66 (98.5) 0.668 (0.068–6.533) 0.726 21 (16.3) 9 (10.8) 1.599 (0.694–3.685) 0.268
Deficient 3 (2.2) 1 (1.5) 108 (83.7) 74 (89.2)
MMR Germline Mutation
No 144 (99.3) 71 (100.0) 0.670 (0.610–0.736) 0.483 104 (79.4) 59 (69.4) 1.697 (0.908–3.175) 0.096
Yes 1 (0.7) 0 (0.0) 27 (20.6) 26 (30.6)
MLH1 Methylation
Unmethylated 131 (96.3) 64 (98.5) 0.409 (0.047–3.577) 0.405 62 (47.3) 48 (56.5) 0.693 (0.400–1.199) 0.189
Methylated 5 (3.7) 1 (1.5) 69 (52.7) 37 (43.5)
BRAF V600E Mutation
No 126 (90.6) 66 (94.3) 0.587 (0.184–1.873) 0.364 67 (53.2) 53 (66.3) 0.579 (0.324–1.034) 0.064
Yes 13 (9.4) 4 (5.7) 59 (46.8) 27 (33.8)
CIMP Status
Negative 91 (92.9) 42 (93.3) 0.929 (0.229–3.770) 0.917 45 (52.3) 34 (60.7) 0.710 (0.359–1.406) 0.325
Positive 7 (7.1) 3 (6.7) 41 (47.7) 22 (39.3)
Survival Status
Alive 95 (65.5) 50 (70.4) 0.782 (0.424–1.444) 0.432 91 (69.5) 57 (67.1) 1.118 (0.622–2.007) 0.710
Deceased 50 (34.5) 21 (29.6) 40 (30.5) 28 (32.9)
aOdds ratio and 95 % confidence interval for methylated versus unmethylated
bOR and 95 % CI given for lowest stage/grade versus highest stage/grade
cProximal tumor location includes lesions up to and including the splenic flexure
dMucinous histology includes the presence of any mucin within the tumor stroma
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marked by both genetic mutations and hypermethylation in
CRC, acquires DNA methylation equally across subtypes.
This is the first study to investigate DNA methylation
of ITF2 in CRC cases. Here, we have established that
ITF2 methylation is a tumor-associated event, being a
rare occurrence in normal tissue DNA. One sample out
of 47 normal colonic tissue samples was methylated, but
this rare occurrence may possibly be due to the field
effect, or field cancerization, in which apparently normal
cells acquire genetic and/or epigenetic alterations and
may eventually progress to cancer. With regards to
tumor methylation of ITF2, we showed that it is associ-
ated with the MSI-H phenotype. ITF2 has been reported
to be a tumor suppressor that can induce cell cycle
arrest and is sometimes lost due to loss of heterozygosity
at 18q21 [31]. However, ITF2 expression has been found
to be upregulated in some cancers with aberrantly acti-
vated Wnt signaling but decreased in others [30, 31].
Further research is required to elucidate the role of ITF2
in tumorigenesis. Treatment of gastric cancer cell lines
with the DNA methyltransferase inhibitor 5-aza-2’-deox-
ycytidine (5-aza) restored mRNA expression in cell lines
that had hypermethylation demonstrating methylation-
dependent regulation of this gene [33]. Thus, transcrip-
tional silencing in CRC through methylation would
likely lead to a decrease in its cellular expression levels
potentially contributing to tumorigenesis.
APC promoter methylation is rarely observed in nor-
mal colonic tissue compared with CRC tumor tissue in
our study population, which replicates the findings of a
recent meta-analysis [44]. However, contrary to ITF2
methylation, we did not see an association with MSI-H
CRC or any other clinical features. APC expression is at
least partially regulated by DNA methylation, as its
expression increases in CRC cell lines after treatment
with 5-aza [45]. Several other studies have investigated
the correlation between APC methylation and MSI with
varying results. Studies have shown wide variation in
overall APC methylation, regardless of subtype, from as
low as 18 % to as high as 63.4 % [19, 20]. Our results
show a more moderate level of 34–40 % of cases methyl-
ated. Findings in the literature for the correlation
between APC and MSI are even less clear, with methyla-
tion in MSI-H tumors ranging from 14.3–72.7 % [21, 26].
However, these studies analyzed small numbers of patient
samples, with a maximum of 29 MSI tumors used [24].
Our study, on the other hand, employed a total of 432
samples, 216 of which were MSI-H. This sample size is
many times larger than any other of its kind, giving more
statistical power and certainty to our results.
There are no differences between level of methylation
at different stages of CRC diagnosis for either APC or
ITF2, indicating these may be early epigenetic events in
tumorigenesis. Additionally, APC methylation has been
detected in colon adenoma, further evidence that it is an
early event [46]. Detection of APC may be further
exploited as a potential biomarker by detection in other
biospecimens, as its methylation has been detected in
both stool and plasma [47, 48]. Further investigation of
the presence of ITF2 methylation in adenomas should
be undertaken, as well as whether its methylation can be
detected in stool or plasma. This research will indicate
the potential of utilizing ITF2 and APC, perhaps in
combination with other methylation markers, as non-
invasive stool- or plasma-based methylation markers
for CRC detection and/or subtype discrimination.
Data from colon and rectal tumors from The Cancer
Genome Atlas (TCGA) shows that APC mutation rates
differ among the 224 tumors sequenced by exome
sequencing. TCGA data described hypermutated tumors,
which have a mutation rate of 12/106 and consist mostly
of MSI-H tumors. The prevalence of APC mutation in
these hypermutated tumors is 51 % [15]. Alternatively,
non-hypermutated tumors, defined by a mutation rate
<8.24/106 and consisting mostly of MSS tumors, in-
curred APC mutations in 81 % of cases [15]. This dispar-
ity in APC mutation rates may be explained by DNA
methylation to inactivate APC leading to constitutive
ligand-independent Wnt signaling. In this same data set
ITF2 is genetically altered in only 3 % of tumors, thus,
methylation is likely to play a larger role in ITF2 dysreg-
ulation in cancer [49, 50].
While MSI-H tumors are a largely well-defined sub-
type of CRC, MSS tumors comprise the majority of cases
and exhibit a wide variety of molecular characteristics.
Thus, there is an emerging research focus to further
classify molecular subtypes of CRC. Recently, four con-
sensus molecular subtypes were defined. The first sub-
type consists mostly of MSI cases [14]. The remaining
three subtypes are defined by ‘canonical’ Wnt and MYC
activation, metabolic dysregulation, or mesenchymal
activation. Our results indicated that some MSS cases
incur methylation of the Wnt genes studied, so perhaps
these cases belong to the subtype characterized by Wnt
activation. It would be interesting to see which sub-
classification the MSS cases used in this study belong to,
and how ITF2 or APC methylation profiles differ among
the four subtypes.
MSI-H tumors often overlap with CIMP-positive
status. Thus, the association we see between MSI-H and
ITF2 methylation may in fact be part of the widespread
hypermethylation of CpG islands that characterizes
CIMP tumors. CIMP status information is unavailable
for some Ontario cases and all Newfoundland cases
utilized in this study, thus we do not have a complete
picture of CIMP for our cohort. From our available data
we did see a trend between CIMP-positive status and
ITF2 methylation among MSS cases. However, there
Savio et al. BMC Cancer  (2016) 16:113 Page 8 of 11
were only ten cases in this group. From our current
findings as well as previous investigation into epigenetic
regulation of Wnt signalling genes we have found that
dysregulation through aberrant methylation is implicated
in all subtypes of CRC, not solely in CIMP-positive cases.
APC, which abrogates Wnt signaling intracellularly, is
methylated in a proportion of CRCs, regardless of subtype
while ITF2, a downstream target of Wnt signaling, is meth-
ylated more often in MSI-H tumors. Our lab has previously
found that DKK1 and SFRP1 promoter methylation, coding
for two extracellular Wnt antagonists, segregate strongly
with different CRC subtypes. DKK1 methylation is associ-
ated with the MSI-H phenotype and other MSI-associated
features, while SFRP1 methylation is associated with MSS
tumors [34]. We also found thatWnt5a methylation, which
codes for an extracellular ligand of the non-canonical Wnt
pathway, is associated with MSI-H [35]. These results were
found in the same cohort of Ontario and Newfoundland
patients used in this study. These observations underscore
the importance of both Wnt signaling and the role of DNA
methylation in CRC.
One limitation of this study to bear in mind is that only
a subset of available MSS cases was chosen for analysis by
matching to MSI-H cases by age quartile, stage and sex.
Individuals with MSI-H CRC are generally a younger age,
more frequently female, have a lower tumor stage and are
more frequently CIMP-positive than those individuals
with MSS tumors. Thus, the MSS cases analyzed in this
study do not wholly represent all MSS cases from our
Ontario and Newfoundland populations. Additionally, we
did not select MSS cases from the entire Ontario cohort,
but only a subset available at the time this study was
undertaken. The subset that we selected from did not dif-
fer in age, sex, stage or CIMP rates from the entire cohort.
The strengths of our study include large sample size,
the inclusion of two independent well-characterized
population-based cohorts and the choice of technol-
ogy. The use of MethyLight technology is superior to
methylation-specific PCR (MSP) and offers several
advantages including a quantitative, high-throughput
methylation-specific real-time PCR-based technique,
which is amenable to using small quantities of DNA
extracted from archival tissue specimens. MSP is a
more qualitative and subjective method that has been
used in many prior studies of APC methylation.
Conclusions
Our findings demonstrate the importance of DNA methyla-
tion in the regulation of genes selected for analysis and its
differing effects based on tumor subtype. ITF2 is not yet
well studied in CRC and we have now shown that this gene
incurs MSI-associated hypermethylation. For APC, both
mutation and methylation play a role in its dysregulation. It
is likely that methylation of APC plays a secondary role in
CRC to more commonly occurring mutations and may act
to fine-tune Wnt signaling. With both mutation and
methylation contributing to regulation of this gene, it is
possible the sequence of events may dictate the way CRC
evolves. Based on its high specificity for CRC, APC methy-
lation may offer usefulness as a marker within a panel of
other genes for CRC detection and ITF2 may be useful for
detection of MSI-H tumors. Future studies to independ-
ently validate these findings are warranted. Overall, this
study has investigated methylation of the Wnt genes APC
and ITF2 in a large cohort of MSI-H and matched MSS
CRC tumors to find that ITF2 methylation is significantly
associated with MSI-H tumors while APC methylation is a
tumor-specific event in CRC, which does not differ signifi-
cantly between MSI-H and MSS subtypes or other clinico-
pathological variables.
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